168 related articles for article (PubMed ID: 23420374)
1. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
5. The neuropeptide genes
Misawa K; Mima M; Imai A; Mochizuki D; Misawa Y; Endo S; Ishikawa R; Kanazawa T; Mineta H
Clin Epigenetics; 2018; 10():52. PubMed ID: 29682090
[TBL] [Abstract][Full Text] [Related]
6. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of galanin receptor 1 in head and neck cancer.
Misawa K; Ueda Y; Kanazawa T; Misawa Y; Jang I; Brenner JC; Ogawa T; Takebayashi S; Grenman RA; Herman JG; Mineta H; Carey TE
Clin Cancer Res; 2008 Dec; 14(23):7604-13. PubMed ID: 19047085
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of
Misawa K; Mochizuki D; Imai A; Misawa Y; Endo S; Mima M; Kawasaki H; Carey TE; Kanazawa T
Clin Epigenetics; 2017; 9():64. PubMed ID: 28616099
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
[TBL] [Abstract][Full Text] [Related]
11. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
[TBL] [Abstract][Full Text] [Related]
12. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
14. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Uehara T; Imai A; Takahashi G; Takebayashi S; Cole A; Carey TE; Mineta H
Transl Oncol; 2013 Jun; 6(3):338-46. PubMed ID: 23730414
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modification of
Misawa K; Misawa Y; Imai A; Mochizuki D; Endo S; Mima M; Ishikawa R; Kawasaki H; Yamatodani T; Kanazawa T
J Cancer; 2018; 9(6):941-949. PubMed ID: 29581773
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
17. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.
Weiss D; Stockmann C; Schrödter K; Rudack C
Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585
[TBL] [Abstract][Full Text] [Related]
18. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H
Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364
[TBL] [Abstract][Full Text] [Related]
20. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]